Physician profile
Mark Dikopf
NPI 1255673364
$3,929.89
in general payments reported to CMS, 2019-2025
30 companies · $672 in 2025
The $672 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $787 · 2020: $269 · 2021: $256 · 2022: $469 · 2023: $625 · 2024: $851 · 2025: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,148.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $729.88 | 2022-2025 | Lumigan, Xen Glaucoma Treatment System, Alphagan P |
| Alcon Vision LLC | $668.06 | 2019-2025 | Rocklatan, Clareon, Hydrus Microstent |
| Allergan, INC. | $471.42 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $243.49 | 2022-2025 | Vyzulta, Prolensa, Lotemax Sm |
| Aerie Pharmaceuticals, INC. | $240.24 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $202.21 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $172.99 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $171.81 | 2023-2024 | Eylea, Eylea Hd |
| Thea Pharma INC. | $117.12 | 2022-2025 | Iyuzeh |
| Harrow Eye, LLC | $106.23 | 2023-2025 | Vevye |
| Apellis Pharmaceuticals, INC. | $99.07 | 2023-2025 | Syfovre |
| Sight Sciences, INC. | $80.97 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Tarsus Pharmaceuticals, INC. | $70.74 | 2024-2025 | Xdemvy |
| New World Medical,INC. | $67.08 | 2020-2025 | Clearpath, Streamline, Kahook Dual Blade |
| Ani Pharmaceuticals, INC. | $63.92 | 2025 | Purified Cortrophin Gel |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $56.19 | 2023-2024 | Cequa |
| Oyster Point Pharma, INC. | $39.24 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $38.79 | 2019-2023 | Tecnis Simplicity |
| Eyevance Pharmaceuticals LLC | $37.19 | 2020-2021 | |
| Genentech USA, INC. | $32.54 | 2025 | Vabysmo |
| Alimera Sciences, INC. | $31.28 | 2024 | Yutiq, Iluvien |
| Mallinckrodt Hospital Products INC. | $29.57 | 2025 | Acthar |
| Pacira Pharmaceuticals Incorporated | $25.77 | 2024 | Exparel |
| Eyepoint US, INC. | $23.92 | 2023 | |
| Dompe US, INC. | $23.58 | 2025 | Oxervate |
| Shire North American Group INC | $21.63 | 2019 | |
| Rxsight INC | $20.61 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Amgen INC. | $18.39 | 2024 | Tepezza |
| The Cameron-Ehlen Group, INC. | $6.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Dikopf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.